Class information for:
Level 1: SUNITINIB//METASTATIC RENAL CELL CARCINOMA//RENAL CELL CARCINOMA

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
727 3131 37.7 83%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
465 3       RENAL CELL CARCINOMA//ANGIOMYOLIPOMA//TUBEROUS SCLEROSIS 24387
318 2             RENAL CELL CARCINOMA//PARTIAL NEPHRECTOMY//KIDNEY NEOPLASMS 18306
727 1                   SUNITINIB//METASTATIC RENAL CELL CARCINOMA//RENAL CELL CARCINOMA 3131

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 SUNITINIB authKW 2727939 20% 44% 637
2 METASTATIC RENAL CELL CARCINOMA authKW 1447814 7% 65% 227
3 RENAL CELL CARCINOMA authKW 1318715 32% 14% 989
4 SORAFENIB authKW 809817 13% 21% 400
5 AXITINIB authKW 585787 3% 57% 106
6 TEMSIROLIMUS authKW 517933 4% 39% 135
7 PAZOPANIB authKW 463235 4% 40% 118
8 CYTOREDUCTIVE NEPHRECTOMY authKW 346389 1% 79% 45
9 RENAL CELL CANCER authKW 290280 4% 22% 137
10 TARGETED THERAPY authKW 232053 11% 7% 343

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Oncology 45787 62% 0% 1937
2 Urology & Nephrology 22869 25% 0% 790
3 Pharmacology & Pharmacy 1021 13% 0% 404
4 Medicine, Research & Experimental 30 2% 0% 76
5 Medicine, General & Internal 21 3% 0% 96
6 Peripheral Vascular Diseases 13 1% 0% 44
7 Hematology 11 1% 0% 45
8 Health Care Sciences & Services 7 1% 0% 24
9 Dermatology 2 1% 0% 23
10 Pathology 0 1% 0% 27

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 SOLID TUMOR ONCOL 122652 3% 14% 87
2 TAUSSIG CANC 111889 4% 8% 137
3 SOLID TUMOR ONCOL UROL 103997 1% 67% 16
4 MED ONCOL 79276 20% 1% 615
5 CLIN HEMATOL HEMOSTASIS ONCOL STEM CELL TRANSPL 74893 0% 59% 13
6 MED ONCOL EXPT THER EUT 52948 1% 23% 24
7 GENITOURINARY ONCOL SERV 52452 2% 11% 47
8 RADIOL ONCOL HUMAN PATHOL 49920 0% 39% 13
9 UROL 49713 24% 1% 752
10 KIDNEY CANC 45366 0% 42% 11

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CLINICAL GENITOURINARY CANCER 222537 4% 18% 125
2 TARGETED ONCOLOGY 34023 1% 9% 38
3 UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 21019 2% 3% 64
4 EXPERT REVIEW OF ANTICANCER THERAPY 20596 2% 4% 59
5 ANNALS OF ONCOLOGY 12448 3% 1% 103
6 EUROPEAN UROLOGY SUPPLEMENTS 12079 1% 5% 27
7 FUTURE ONCOLOGY 9962 1% 3% 38
8 ONCOLOGIST 7711 1% 2% 42
9 EUROPEAN UROLOGY 7108 2% 1% 73
10 UROLOGE 6869 1% 2% 36

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 SUNITINIB 2727939 20% 44% 637 Search SUNITINIB Search SUNITINIB
2 METASTATIC RENAL CELL CARCINOMA 1447814 7% 65% 227 Search METASTATIC+RENAL+CELL+CARCINOMA Search METASTATIC+RENAL+CELL+CARCINOMA
3 RENAL CELL CARCINOMA 1318715 32% 14% 989 Search RENAL+CELL+CARCINOMA Search RENAL+CELL+CARCINOMA
4 SORAFENIB 809817 13% 21% 400 Search SORAFENIB Search SORAFENIB
5 AXITINIB 585787 3% 57% 106 Search AXITINIB Search AXITINIB
6 TEMSIROLIMUS 517933 4% 39% 135 Search TEMSIROLIMUS Search TEMSIROLIMUS
7 PAZOPANIB 463235 4% 40% 118 Search PAZOPANIB Search PAZOPANIB
8 CYTOREDUCTIVE NEPHRECTOMY 346389 1% 79% 45 Search CYTOREDUCTIVE+NEPHRECTOMY Search CYTOREDUCTIVE+NEPHRECTOMY
9 RENAL CELL CANCER 290280 4% 22% 137 Search RENAL+CELL+CANCER Search RENAL+CELL+CANCER
10 TARGETED THERAPY 232053 11% 7% 343 Search TARGETED+THERAPY Search TARGETED+THERAPY

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 MOTZER, RJ , ESCUDIER, B , GANNON, A , FIGLIN, RA , (2017) SUNITINIB: TEN YEARS OF SUCCESSFUL CLINICAL USE AND STUDY IN ADVANCED RENAL CELL CARCINOMA.ONCOLOGIST. VOL. 22. ISSUE 1. P. 41 -52 72 85% 0
2 SUN, M , LUGHEZZANI, G , PERROTTE, P , KARAKIEWICZ, PI , (2010) TREATMENT OF METASTATIC RENAL CELL CARCINOMA.NATURE REVIEWS UROLOGY. VOL. 7. ISSUE 6. P. 327 -338 72 85% 53
3 CZARNECKA, AM , KAWECKI, M , LIAN, F , KORNILUK, J , SZCZYLIK, C , (2015) FEASIBILITY, EFFICACY AND SAFETY OF TYROSINE KINASE INHIBITOR TREATMENT IN HEMODIALYZED PATIENTS WITH RENAL CELL CANCER: 10 YEARS OF EXPERIENCE.FUTURE ONCOLOGY. VOL. 11. ISSUE 16. P. 2267 -2282 58 89% 7
4 ALBIGES, L , CHOUEIRI, T , ESCUDIER, B , GALSKY, M , GEORGE, D , HOFMANN, F , LAM, T , MOTZER, R , MULDERS, P , PORTA, C , ET AL (2015) A SYSTEMATIC REVIEW OF SEQUENCING AND COMBINATIONS OF SYSTEMIC THERAPY IN METASTATIC RENAL CANCER.EUROPEAN UROLOGY. VOL. 67. ISSUE 1. P. 100 -110 41 98% 26
5 ESCUDIER, B , SZCZYLIK, C , PORTA, C , GORE, M , (2012) TREATMENT SELECTION IN METASTATIC RENAL CELL CARCINOMA: EXPERT CONSENSUS.NATURE REVIEWS CLINICAL ONCOLOGY. VOL. 9. ISSUE 6. P. 327 -337 57 88% 47
6 SHINOHARA, N , ABE, T , (2015) PROGNOSTIC FACTORS AND RISK CLASSIFICATIONS FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA.INTERNATIONAL JOURNAL OF UROLOGY. VOL. 22. ISSUE 10. P. 888 -897 79 69% 1
7 DIEKSTRA, MHM , SWEN, JJ , GELDERBLOM, H , GUCHELAAR, HJ , (2016) A DECADE OF PHARMACOGENOMICS RESEARCH ON TYROSINE KINASE INHIBITORS IN METASTATIC RENAL CELL CANCER: A SYSTEMATIC REVIEW.EXPERT REVIEW OF MOLECULAR DIAGNOSTICS. VOL. 16. ISSUE 5. P. 605 -618 54 75% 4
8 CZARNECKA, AM , SZCZYLIK, C , RINI, B , (2014) THE USE OF SUNITINIB IN RENAL CELL CARCINOMA: WHERE ARE WE NOW?.EXPERT REVIEW OF ANTICANCER THERAPY. VOL. 14. ISSUE 9. P. 983 -999 71 76% 2
9 VAN DER MIJN, JC , MIER, JW , BROXTERMAN, HJ , VERHEUL, HM , (2014) PREDICTIVE BIOMARKERS IN RENAL CELL CANCER: INSIGHTS IN DRUG RESISTANCE MECHANISMS.DRUG RESISTANCE UPDATES. VOL. 17. ISSUE 4-6. P. 77 -88 65 75% 13
10 THURET, R , MAURIN, C , SUN, M , PERROTTE, P , KARAKIEWICZ, PI , (2011) TREATMENT OF METASTATIC RENAL CELL CARCINOMA.PROGRES EN UROLOGIE. VOL. 21. ISSUE 4. P. 233 -244 68 85% 2

Classes with closest relation at Level 1


Rank Class id link
1 18265 VANDETANIB//NINTEDANIB//CEDIRANIB
2 6508 RENAL CELL CARCINOMA//CARCINOMA RENAL CELL//RENAL CELL
3 17657 BEVACIZUMAB//METASTATIC BREAST CANCER//APATINIB
4 23991 REGORAFENIB//N DESETHYL SUNITINIB//N DESMETHYL IMATINIB
5 18991 RECIST//RECIST 11//TARGET LESION
6 35514 AG 1295//BONE CANC SMYELOMA//CAREGGI UNIV HOSP INTERNAL MEDAOU CAREGGI
7 16698 TRICHOMEGALY//EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS//SKIN TOXICITY
8 1471 INTERLEUKIN 2//LYMPHOKINE ACTIVATED KILLER CELLS//RECOMBINANT INTERLEUKIN 2
9 27586 BAP1//SETD2//BRCA1 ASSOCIATED PROTEIN 1
10 4929 SORAFENIB//HEPATOCELLULAR CARCINOMA//HEPATIC ARTERIAL INFUSION CHEMOTHERAPY

Go to start page